Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2026
Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data AnalysisYago Garitaonaindia, Rikke Andersen, Mario Presti, et al.
Expert Opinion on Biological Therapy|April 13, 2022
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directionsJoachim Stoltenborg Granhøj, Agnete Witness Præst Jensen, Mario Presti, et al.
Cancer Immunology, Immunotherapy : CII|November 9, 2020
The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitroMario Presti, Marie Christine Wulff Westergaard, Arianna Draghi, et al.
Trends in Molecular Medicine|April 24, 2025
Acquired resistance to immunotherapy in solid tumorsPerrine Verdys, Astrid Z Johansen, Anurag Gupta, et al.
Oncology Letters|August 22, 2018
Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastomaMario Presti, Emanuela Mazzon, Maria Sofia Basile, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2025
Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanomaRasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, et al.
Brain Sciences|September 5, 2019
Prediction of PD-L1 Expression in Neuroblastoma via Computational ModelingSalvo Danilo Lombardo, Mario Presti, Katia Mangano, et al.
International Journal of Molecular Sciences|September 7, 2019
Modulation of Tetraspanin 32 (TSPAN32) Expression in T Cell-Mediated Immune Responses and in Multiple SclerosisSalvo Danilo Lombardo, Emanuela Mazzon, Maria Sofia Basile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in MelanomaArianna Draghi, Mario Presti, Agnete W P Jensen, et al.
Cancer Immunology Research|August 15, 2022
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 ImmunotherapyMorten Nielsen, Mario Presti, Zsofia Sztupinszki, et al.
Pageof 2